Clinical Relevance of Steroid Use in Neuro-Oncology

[1]  Eudocia Q Lee,et al.  Assessment of Brain Tumor Response: RANO and Its Offspring , 2016, Current Treatment Options in Oncology.

[2]  R. Stupp,et al.  Corticosteroids compromise survival in glioblastoma. , 2016, Brain : a journal of neurology.

[3]  S. Parsons,et al.  Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients , 2015, Radiation oncology.

[4]  P. Brown,et al.  The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic. , 2015, Neuro-oncology.

[5]  L. Leibovici,et al.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. , 2014, The Cochrane database of systematic reviews.

[6]  J. Buatti,et al.  ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases. , 2014, Journal of palliative medicine.

[7]  S. Ajeganova,et al.  Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial , 2014, BMJ Open.

[8]  W. Roa,et al.  Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline. , 2014, Current oncology.

[9]  Antonio Pérez,et al.  Glucocorticoid‐induced hyperglycemia (糖皮质激素诱导的高血糖) , 2014, Journal of diabetes.

[10]  N. Ishizuka,et al.  Rates of Serious Intracellular Infections in Autoimmune Disease Patients Receiving Initial Glucocorticoid Therapy , 2013, PloS one.

[11]  Michael Meyer-Hermann,et al.  In Silico Analysis of Cell Cycle Synchronisation Effects in Radiotherapy of Tumour Spheroids , 2013, PLoS Comput. Biol..

[12]  Hans Skovgaard Poulsen,et al.  Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution , 2013, BMC Cancer.

[13]  L. Recht,et al.  Steroid-sparing effect of corticorelin acetate in peritumoral cerebral edema is associated with improvement in steroid-induced myopathy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  I. Petersen,et al.  Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. , 2012, The American journal of psychiatry.

[15]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[16]  S. Pastorino,et al.  Corticosteroids in brain cancer patients: benefits and pitfalls , 2011, Expert review of clinical pharmacology.

[17]  T. Mikkelsen,et al.  Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. , 2010, The oncologist.

[18]  I. Wilkinson,et al.  A Systematic Review of the Literature on the Effects of Dexamethasone on the Brain From In Vivo Human-Based Studies: Implications for Physiological Brain Imaging of Patients With Intracranial Tumors , 2010, Neurosurgery.

[19]  A. Carpentier,et al.  Steroid requirements during radiotherapy for malignant gliomas , 2010, Journal of Neuro-Oncology.

[20]  D. Kondziolka,et al.  The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline , 2009, Journal of Neuro-Oncology.

[21]  Renato Malcher-Lopes,et al.  Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch. , 2008, European journal of pharmacology.

[22]  D. Long,et al.  GENESIS OF THE USE OF CORTICOSTEROIDS IN THE TREATMENT AND PREVENTION OF BRAIN EDEMA , 2008, Neurosurgery.

[23]  L. Muglia,et al.  Glucocorticoids differentially regulate degradation of MyoD and Id1 by N-terminal ubiquitination to promote muscle protein catabolism , 2008, Proceedings of the National Academy of Sciences.

[24]  G. Pond,et al.  The use and toxicity of steroids in the management of patients with brain metastases , 2008, Supportive Care in Cancer.

[25]  A. Flahault,et al.  Corticosteroid‐induced clinical adverse events: frequency, risk factors and patient’s opinion , 2007, The British journal of dermatology.

[26]  J. Bilezikian,et al.  Glucocorticoid-induced osteoporosis: pathophysiology and therapy , 2007, Osteoporosis International.

[27]  A. Raslan,et al.  Medical management of cerebral edema. , 2007, Neurosurgical focus.

[28]  M. Bastin,et al.  Quantitative assessment of intracranial tumor response to dexamethasone using diffusion, perfusion and permeability magnetic resonance imaging. , 2007, Magnetic resonance imaging.

[29]  M. Kulke,et al.  Selective Lymphopenia and Opportunistic Infections in Neuroendocrine Tumor Patients Receiving Temozolomide , 2007, Cancer investigation.

[30]  Jeffrey R Curtis,et al.  Population-based assessment of adverse events associated with long-term glucocorticoid use. , 2006, Arthritis and rheumatism.

[31]  J. Leers,et al.  Glucocorticoid effects on mouse microvascular endothelial barrier permeability are brain specific , 2006, The Journal of physiology.

[32]  T. Cloughesy,et al.  MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy , 2006, Neurology.

[33]  I. Wilkinson,et al.  Dexamethasone and Enhancing Solitary Cerebral Mass Lesions: Alterations in Perfusion and Blood-tumor Barrier Kinetics Shown by Magnetic Resonance Imaging , 2006, Neurosurgery.

[34]  E. Canalis.  Mechanisms of glucocorticoid action in bone , 2005, Annals of the New York Academy of Sciences.

[35]  J. Cidlowski,et al.  The human glucocorticoid receptor: One gene, multiple proteins and diverse responses , 2005, Steroids.

[36]  E. Sribnick,et al.  Dexamethasone decreases temozolomide‐induced apoptosis in human gliobastoma T98G cells , 2005, Glia.

[37]  Frieder Keller,et al.  Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids , 2005, Clinical Pharmacokinetics.

[38]  R. Moots,et al.  Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions , 2004, Annals of the rheumatic diseases.

[39]  C. Cooper,et al.  The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis , 2002, Osteoporosis International.

[40]  K. Sepkowitz.  Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  C. Hess,et al.  Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? , 2002, Supportive Care in Cancer.

[42]  M. Weller,et al.  Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells , 2001, Oncogene.

[43]  C. Cooper,et al.  Use of Inhaled Corticosteroids and Risk of Fractures , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  E. Brown,et al.  Mood and Cognitive Changes During Systemic Corticosteroid Therapy. , 2001, Primary care companion to the Journal of clinical psychiatry.

[45]  L. Ellis,et al.  Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. , 2000, Cancer research.

[46]  A. Thorburn,et al.  Dexamethasone inhibits insulin-like growth factor signaling and potentiates myoblast apoptosis. , 2000, Endocrinology.

[47]  D. Walsh,et al.  Symptom control in advanced cancer: important drugs and routes of administration. , 2000, Seminars in oncology.

[48]  T. Kokunai,et al.  Relationship between Expression of p21WAF1/CIP1 and Radio resistance in Human Gliomas , 1999, Japanese journal of cancer research : Gann.

[49]  A. Guha,et al.  Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. , 1997, Neurosurgery.

[50]  D. Allen.  Growth suppression by glucocorticoid therapy. , 1996, Endocrinology and metabolism clinics of North America.

[51]  G. Criscuolo,et al.  Vascular endothelial growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cysts. , 1995, Journal of neurosurgery.

[52]  J. Cairncross,et al.  Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  W. van Putten,et al.  Dose‐effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors , 1994, Neurology.

[54]  D. Furst,et al.  Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. , 1994, The American journal of medicine.

[55]  J. Whitworth.  Adrenocorticotrophin and steroid-induced hypertension in humans. , 1992, Kidney international. Supplement.

[56]  B. Erickson,et al.  Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases , 1991, Journal of Neuro-Oncology.

[57]  S. Soong,et al.  Steroid‐induced weakness in patients with primary brain tumors , 1991, Neurology.

[58]  J. Henson,et al.  Pneumocystis carinii pneumonia in patients with primary brain tumors. , 1991, Archives of neurology.

[59]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  D. Cummings,et al.  Characterization of Dexamethasone Binding in Normal and Uremic Human Serum , 1990, DICP : the annals of pharmacotherapy.

[61]  D J Brooks,et al.  Dexamethasone treatment of brain tumor patients , 1985, Neurology.

[62]  Y. Ichikawa,et al.  Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure. , 1985, The Journal of clinical endocrinology and metabolism.

[63]  M. Eadie,et al.  Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[64]  T C Chalmers,et al.  Association of adrenocorticosteroid therapy and peptic-ulcer disease. , 1983, The New England journal of medicine.

[65]  J. Gustafsson,et al.  A study of glucocorticoid receptors in intracranial tumors. , 1981, Journal of neurosurgery.

[66]  A. Young,et al.  Phenytoin-dexamethasone interaction: a previously unreported observation. , 1981, Surgical neurology.

[67]  M. Newmark,et al.  Drug Spotlight Program: The Use of Antiepileptic Drugs , 1979 .

[68]  J. Melby.  Drug spotlight program: systemic corticosteroid therapy: pharmacology and endocrinologic considerations. , 1974, Annals of internal medicine.

[69]  E. Werk,et al.  Interference in the effect of dexamethasone by diphenylhydantoin. , 1969, The New England journal of medicine.

[70]  J. Melby,et al.  Use of dexamethasone in treatment of cerebral edema associated with brain tumors. , 1961, The Journal-lancet.

[71]  S. Taylor,et al.  Treatment of cerebral metastases from breast carcinoma with prednisolone. , 1957, Journal of the American Medical Association.

[72]  R. Mclaurin,et al.  Cortisone and ACTH as an adjunct to the surgery of craniopharyngiomas. , 1952, The New England journal of medicine.

[73]  M. Abrahamowicz,et al.  Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. , 2013, Rheumatology.

[74]  J. Uhm.  Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .

[75]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[76]  I. Piper,et al.  The contribution of arachidonic acid to the aetiology and pathophysiology of focal brain oedema; studies using an infusion oedema model , 2005, Acta Neurochirurgica.

[77]  S. Powell,et al.  The biology of radioresistance: similarities, differences and interactions with drug resistance , 2004, Cytotechnology.

[78]  K. Carson,et al.  A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas. , 2002, Neuro-oncology.

[79]  H. Hirschberg,et al.  Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy. , 1993, Acta oncologica.

[80]  B. McEwen,et al.  Non-genomic and genomic effects of steroids on neural activity. , 1991, Trends in pharmacological sciences.

[81]  T. Ohnishi,et al.  Possible mechanism of vasogenic brain oedema induced by arachidonic acid. , 1990, Acta Neurochirurgica Supplementum.

[82]  S. R. Freidberg,et al.  Glucocorticoid dependency as a prognostic factor in radiotherapy for cerebral gliomas. , 1989, Acta oncologica.

[83]  H H MERRITT,et al.  The use of antiepileptic drugs. , 1949, Bulletin of the New York Academy of Medicine.